MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells

por Versano, Ziv, Shany, Eitan, Freedman, Shany, Tuval-Kochen, Liron, Leitner, Moshe, Paglin, Shoshana, Toren, Amos, Yalon, Michal
Publicado 2018

Eukaryotic Initiation Factor 2α - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment

por Tuval-Kochen, Liron, Paglin, Shoshana, Keshet, Gilmor, Lerenthal, Yaniv, Nakar, Charles, Golani, Tamar, Toren, Amos, Yahalom, Joachim, Pfeffer, Raphael, Lawrence, Yaacov
Publicado 2013

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

por Yalon, Michal, Tuval-Kochen, Liron, Castel, David, Moshe, Itai, Mazal, Inbal, Cohen, Osher, Avivi, Camila, Rosenblatt, Kineret, Aviel-Ronen, Sarit, Schiby, Ginette, Yahalom, Joachim, Amariglio, Ninette, Pfeffer, Raphael, Lawrence, Yaacov, Toren, Amos, Rechavi, Gideon, Paglin, Shoshana
Publicado 2016

Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

por Yalon, Michal, Tuval-Kochen, Liron, Castel, David, Moshe, Itai, Mazal, Inbal, Cohen, Osher, Avivi, Camila, Rosenblatt, Kineret, Aviel-Ronen, Sarit, Schiby, Ginette, Yahalom, Joachim, Amariglio, Ninette, Pfeffer, Raphael, Lawrence, Yaacov R., Toren, Amos, Rechavi, Gideon, Paglin, Shoshana
Publicado 2016